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Abstract
The aim of this study was to search for lipid signatures in blood plasma from cystic fibrosis (CF) patients using a novel
MALDI-TOF-ClinProTools
TM strategy, initially developed for protein analysis, and thin layer chromatography coupled to
MALDI-TOF (TLC-MALDI). Samples from 33 CF patients and 18 healthy children were subjected to organic extraction and
column chromatography separation of lipid classes. Extracts were analyzed by MALDI-TOF, ion signatures were compared
by the ClinProTools
TM software and by parallel statistical analyses. Relevant peaks were identified by LC-MSn. The ensemble
of analyses provided 11 and 4 peaks differentially displayed in CF vs healthy and in mild vs severe patients respectively. Ten
ions were significantly decreased in all patients, corresponding to 4 lysophosphatidylcholine (18:0, 18:2, 20:3, and 20:5) and
6 phosphatidylcholine (36:5, O-38:0, 38:4, 38:5, 38:6, and P-40:1) species. One sphingolipid, SM(d18:0), was significantly
increased in all patients. Four PC forms (36:3, 36:5, 38:5, and 38:6) were consistently downregulated in severe vs mild
patients. These observations were confirmed by TLC-MALDI. These results suggest that plasma phospholipid signatures may
be able to discriminate mild and severe forms of CF, and show for the first time MALDI-TOF-ClinProTools
TM as a suitable
methodology for the search of lipid markers in CF.
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Introduction
Cystic fibrosis (CF) is characterized by a vicious circle of chronic
inflammation in pulmonary airways and recurrent exacerbations,
usually concomitant with bacterial infections [1–3]. These mani-
festations account for the most part of morbidity and mortality
associated with the disease. CF is attributed to mutations in the
CFTR gene, coding for the Cystic Fibrosis Transmembrane
Regulator, a multifunctional transmembrane chloride channel [4].
Nevertheless there is no direct correlation between the presence of a
particular mutation and the severity status [5]. A significant
improvement of clinical parameters, such as FEV1, and of life
expectancy has been obtained in the last decades. Nearly twenty
products are currently in the clinical trial pipeline, covering channel
functionrepair,rescueofCFTR protein,genetherapy,antibacterial
and anti-inflammatory strategies, as reported by the Cystic
Fibrosis Foundation (http://www.cff.org/treatments/Pipeline/).
The choice of a particular strategy should be made depending on
individual characteristics of patients. This prompts the need of their
phenotypical characterization based on the search for markers that
could predict the evolution of the disease. An early marker of
exacerbations or a prognostic indicator could be extremely helpful
in establishing the most adapted treatment for each particular case,
aiming at limiting lung damage. At the beginning of the decade
studies for protein biomarkers in body fluids by non-invasive
methodswereinitiated.Proteinslikemyeloperoxidase,IL-8,cleaved
alpha-antitrypsin, and S100A8 (or CF antigen), have been found in
sputum as predictors of pulmonary exacerbations [6], or associated
with the presence of CFTR mutations [7,8], in addition to
proteomic signatures in serum corresponding to inflammation
markers [9]. Other proteins differentially expressed in target tissues
of CF before the appearance of any sign of the disease, like annexin-
1 (also found cleaved in the sputum of CF patients) [10], cytosolic
phospholipase A2a [10], cytokeratins 8 and 18 [11], peroxiredoxin
6 [12] may also be part of a proteomic signature. More recently,
mass spectrometry analysis of sputum has revealed a proline-
glycine-proline peptide (PGP), an extracellular matrix-derived
neutrophil attractant, as a marker of inflammatory exacerbation
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profiles[14–17],andotherlipid moieties (reviewedin[18,19])inCF
patients and models have been consistently reported, no systematic
search by comprehensive lipidomic techniques has been performed
to date.
The progress in mass spectrometry in the last years has
democratized these techniques. They are now currently used to
answer not only chemistry-related questions, but also in biology
and the medical field. They allow the detection, identification and
quantification of less abundant molecules important in cell
signaling and homeostasis. Matrix-Assisted Laser Desorption
Ionization Time of Flight (MALDI-TOF) mass spectrometry
(MS) has proven effective in the analysis of most lipid classes [20].
However it has not been extensively utilized for lipid analysis as
compared to other ionization methods, such as electrospray (ESI)
or electron impact (EI). MALDI presents several advantages with
respect to other mass spectrometry approaches, such as rapidness
and reproducibility, which makes it especially suitable in studies
involving a large number of samples. A novel application of
MALDI, coupling thin layer chromatography and mass spectrom-
etry (TLC-MALDI) reveals as an interesting alternative when
searching for specific differences in individual lipid molecules. This
technology has recently been developed and applied to the analysis
of lipids in stem cells [21].
In the present study we use for the first time a combination of
MALDI-TOF, TLC-MALDI and ESI-MS/MS on plasma
samples from CF patients and control individuals in the search
for lipid signatures associated with the presence of CFTR
mutations and with the severity of the respiratory disease
characteristic of CF.
Table 1. Clinical data of CF patients (n.i.: not identified; n.d.: not determined).
code gender
age at
inclusion
tanner
stage genotype
pancreatic
function BMI
% ideal weight
for height
pulmonary
disease FEV1% Shwachman score
cf32 M 0,54 1 F508del/F508del PI 12,3 69 severe n.d. 70
cf38 M 0,55 1 F508del/F508del PS 18,4 99,1 mild n.d. 95
cf39 M 3,06 1 F508del/F508del PI 15,3 93 mild n.d. 85
cf42 F 11,14 1 F508del/F508del PI 16,9 95,7 severe 76 65
cf44 F 7,11 1 F508del/F508del PI 17,9 109 mild 113 85
cf47 M 13,57 3 F508del/F508del PI 16,9 92 severe 121 65
cf48 M 10,69 1 F508del/F508del PI 15,2 91 severe 85 65
cf51 M 1,05 1 F508del/F508del PI 13,7 76,8 severe n.d. 60
cf52 M 4,02 1 F508del/IVS8-ST PS 12,8 81 mild n.d. 75
cf60 M 6,26 1 F508del/F508del PI 17 119 mild 116 90
cf64 F 5,14 1 F508del/F508del PI 15 100 mild n.d. 80
cf65 F 1,79 1 F508del/F508del PI 15 88,1 mild n.d. 75
cf69 M 7,23 1 F508del/F508del PI 16,1 101,6 mild 94 90
cf70 F 5,07 1 F508del/F508del PI 14,5 97,3 severe n.d. 80
cf73 F 18,86 5 F508del/N1303K PI 20 97,4 severe 100 65
cf74 M 9,70 1 F508del/N1303K PS 17,2 97,7 mild 121 75
cf79 M 7,37 1 F508del/F508del PI 14,5 100 severe n.d. 80
cf93 M 17,07 5 F508del/F508del PI 23,4 102 mild 87 90
cf96 M 10,48 1 F508del/n.i. PI 14 92,6 mild 89 70
cf97 M 10,48 1 F508del/n.i. PI 13,7 91,1 mild 86 70
cf104 F 23,48 5 F508del/2184ins PI 21,05 n.d. mild 110 90
cf106 F 17,74 4 F508del/2184ins PI 14,4 71,1 severe 23,3 40
cf110 F 2,08 1 F508del/2143d/T PI 16,6 106 mild n.d. 80
cf114 F 0,91 1 F508del/R347P PI 15,5 90,6 mild n.d. 85
cf123 F 16,45 4 F508del/F508del PI 20,9 101 mild 90 80
cf124 F 17,58 1 F508del/F508del PI 21,1 102 mild 110 90
cf127 M 11,82 1 3849+10kB/n.i. PI 11,9 78 severe 37 65
cf136 M 2,14 1 F508del/n.i. PI 14,8 93,3 mild n.d. 75
cf142 F 4,57 F508del/F508del PI 14,8 93 mild n.d. 85
cf147 M 6,89 1 F508del/R1066C PI 18,5 102 mild n.d. 80
cf148 M 0,16 1 F508del/R1066C PI 14,6 94 mild n.d. 85
cf151 F 4,38 1 F508del/F508del PI 15,2 98 mild n.d. 90
cf152 F 2,41 1 F508del/F508del PI 14,2 88,4 mild n.d. 70
doi:10.1371/journal.pone.0007735.t001
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Ethics Statement
All protocols were approved by the Komisja Bioetyczna przy
Instytucie Matki i Dziecka w Warszawie (ethical committee,
Institute for Mother and Child, Warsaw, Poland). All patients
involved in the study or their parents or legal guardians signed a
written consent form.
Patient Description and Sample Collection
Blood plasma samples were collected from CF patients and their
relatives (including healthy siblings) at the Institute of Mother and
Child (Warsaw, Poland) using a standard clinical protocol. Patients
were categorized into mild (no more than 2 pulmonary
exacerbations a year requiring intravenous antibiotics) and severe
(more than 2 pulmonary exacerbations a year requiring intrave-
nous antibiotics, persistent inflammatory changes in lungs,
bronchiectasis, hemoptisis, hemorragia). All patients were at a
good nutritional status, and out of exacerbation period at the time
of collection. All pancreatic sufficient patients at the time of the
study developed pancreatic insufficiency at a later stage. The
analysis was performed on samples from 18 healthy, 33 mild, and
10 severe individuals (Patients’ description is presented in Table 1).
Sample collection was carried out with appropriate ethical
committee approval. Samples were collected in VACUETTEH
EDTA tubes K3E/EDTA K3 (Greiner Bio-One, Kremsmu ¨nster,
Austria) and centrifuged at 2800 g for 15 min at 4uC. Plasma was
separated and dispensed into 200-ml aliquots so that each aliquot
was subjected to a single freezing-thawing cycle. Plasma samples
were frozen in liquid nitrogen and stored at 280uC. The
subsequent analytical procedure is schematically represented in
Figure 1.
Lipid Extraction and Separation
Aliquots of 100 ml were subjected to organic extraction and
purification allowing the sequential enrichment of different groups
of molecules. Organic extraction was performed by addition of 6
volumes of chloroform:methanol (2:1. v/v). The organic phase was
loaded onto a LC-NH2 aminopropyl column (Supelco, Bellefonte,
PA), and three fractions enriched respectively in neutral lipids
(#1), free fatty acids (#2) and neutral phospholipids, i.e.
phosphatidylcholine, phosphatidylethanolamine and sphingomy-
elin (#3), were sequentially eluted with chloroform:isopropanol
Figure 1. Flow diagram describing the experimental proce-
dures.
doi:10.1371/journal.pone.0007735.g001
Table 2. Peaks differentially displayed in either healthy controls vs CF patients (*) or in CF mild vs CF severe patients (**) with
p,0.05 after T-test analysis.
m/z D(m/z) Relative abundance Identity
non-CF CF CF mild CF severe
482.49 0.13 0.0560.08 0.360.49* 0.2660.43 0.3860.63 LPC(O-16:0) or LPE(18:0)
489.27 0.07 0.0660.21 0.2960.41* 0.2760.44 0.3360.35 SM(d18:0)
520.31 0.02 2.9963.13 0.761* 0.8461.14 0.9862.1 LPC(18:2)
524.35 0.02 2.5362.59 0.7761.28* 0.9761.44 0.6161.24 LPC(18:0)
542.3 0.02 2.1861.62 0.8160.98* 0.9461.07 0.4560.56 LPC(20:5)
544.31 0.02 1.7461.08 0.860.88* 0.9660.96 0.5160.53 LPC(20:4)
546.33 0.02 1.2860.97 0.5860.62* 0.760.67 0.2960.3 LPC(20:3)
725.5 0.03 5.5464.18 3.6162.83 4.4162.87 1.5261.26** SM(16:0)
780.53 0.01 34.18614.25 21.84620.71* 26.31622.72 10.4463.84** PC(36:5)
782.52 0.02 27.1467.67 21.74615.82 25.86616.86 12.3865.15** PC(36:4)
784.54 0.02 21.0766.07 17.68612.01 21.28612.12 9.7766.07** PC(36:3)
786.59 0.01 10.6469.01 4.6364.34* 5.9664.38 5.27613.07 PC(36:2)
804.54 0.13 7.164.13 4.1263* 563.01 1.7661.07** PC(O-38:0)
806.56 0.00 9.5463.98 6.4164.55* 7.9264.43 2.8961.94** PC(38:6)
808.58 0.00 18.8867.49 12.4568.82* 15.2968.6 5.6663.68** PC(38:5)
810.6 0.01 5.7761.83 3.6362.87* 4.5562.77 1.9562.51 PC(38:4)
828.56 0.11 1.6661.37 0.5360.46* 0.5960.51 0.3260.22 PC(P-40:1)
832.56 0.16 3.0261.85 1.7861.64 2.1461.73 0.860.83** PC(O-40:0)
All peaks are [M+H]
+ except 489.27 and 725.53, which correspond to [M+Na]
+. # Theoretical identity (not confirmed by MS
n).
doi:10.1371/journal.pone.0007735.t002
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respectively, according to a method described elsewhere [22].
Mass Spectrometry Analysis
Extracts were subjected to MALDI-TOF MS in both negative
and positive modes in order to obtain signatures characteristic of
any of the groups of individuals. Organic extracts were evaporated
to dryness, resuspended in an equal volume of chloroform:metha-
nol (2:1. v/v) and loaded on the MALDI target in combination
with 1 volume of 0.5 M dihydrobenzoic acid (DHB) in methanol
with 0.1% trifluoroacetic acid as the matrix. Although this matrix
is specific for positive ionization, data were acquired in both the
positive and negative reflectron mode between 200 and 2000 m/z
in an AutoFlex MALDI-TOF mass spectrometer (Bruker Dal-
tonics), using a low molecular weight peptide mixture (Peptide
Mix-5, LaserBioLabs, Sophia-Antipolis, France) for calibration.
Two MS signatures (in the positive and negative modes) were
obtained from each extract fraction.
Signature Comparisons and Statistical Analyses
Signatures corresponding to the different patient and control
groups were compared by the ClinProTools
TM software (Bruker
Daltonics). This tool recalibrates and normalizes all spectra to
their own total ion count, performs a statistical calculation and
provides the significant differences for each ion peak among the
groups of individuals considered. Statistical significance of
differential displayed peaks was determined by either Student T-
Test for 2 groups, or by ANOVA, for more than 2 groups.
ClinProTools-independent statistical analyses were performed
with the R system (v2.9) and Bioconductor software packages (V2.4)
[23,24]. Peak amplitudes were log-transformed to normalize
distributions. Analysis of variance (ANOVA) with robust variance
estimation of the three groups of subjects was performed with the
LIMMA package [25] to identify peaks differentially displayed. P
values were established after false discovery rate correction. Those
peaks showing p,0.05 were considered to present statistically
significant differences. Hierarchical clustering was performed after
Figure 2. A: Representative LC/MSn analysis of 1-palmitoyl,2-arachidonoyl-phosphatidylcholine in human plasma sample. This PC
species was detected as protonated molecular ion in the positive ion mode. MS2 yielded product ions deriving from the neutral loss of the
trimethylammonium and the phosphocholine head group. B: Identification of 1-palmitoyl,2-arachidonoyl PC (m/z 840.5) in human plasma samples.
LC/MS chromatogram (upper panel) and fragmentation pattern in MS2 and MS3 using an ion trap instrument (upper and medium panels). PC species
were detected as acetate adducts of the molecular ions using ESI set in the negative mode. The MS2 fragmentation pattern is characterized by
neutral loss of the acetate adduct of the N-methyl group (medium panel). MS3 of the ion with m/z 766.5 yields the lysophospholipid with neutral loss
of ketene in combination with the sn21 and sn22 carboxylate anions (lower panel). Extraction of the LC/MS3 chromatogram allows to distinguish
between different isomers (upper panel). Abbreviations: R1,a=sn21 aliphatic chain; R2,b=sn22 aliphatic chain.
doi:10.1371/journal.pone.0007735.g002
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Algorithm and a distance defined by the correlation coefficient for
peaks and an euclidean distance for samples.
Peak Identification by Liquid Chromatography – Mass
Spectrometry (LC-MS
n)
LC-MS
n was performed in an 1100-LC system equipped with
an Ion Trap XCT (Agilent Technologies). Lipids were separated
using a Poroshell 300 SB C18 column (2.1675 mm inner
diameter, 5 mm; Agilent Technologies, Wilmington, DE) main-
tained at 50uC. A linear gradient of methanol in water containing
5 mM ammonium acetate and 0.25% acetic acid (from 85% to
100% of methanol in 4 min) was applied at a flow rate of 1 ml/
min. Detection was set in either the positive or the negative mode.
N2 was used as drying gas at a flow rate of 12 l/min, with
temperature of 350uC and nebulizer pressure of 60 p.s.i. Helium
was used as the collision gas. Lipids were identified by comparison
of their LC retention times and MSn fragmentation patterns with
those of authentic standards as previously described [26,27].
Detection and analysis were controlled by Agilent/Bruker
Daltonics software version 5.2. Briefly, in positive ESI mode, PC
species were detected as protonated molecular ions and MS
2
yielded product ions deriving from the neutral loss of the
trimethylammonium and the phosphocholine head group. Using
ESI set in negative mode, PC species were detected as acetate
adducts of the molecular ions. The MS
2 fragmentation pattern of
PC species is characterized by neutral loss of the acetate adduct of
the N-methyl group. MS3 of the ion [M-H-CH3]
2 yields the
lysophospholipid with neutral loss of ketene in combination with
the sn-1 and sn-2 carboxylate anions.
Thin Layer Chromatography – MALDI (TLC-MALDI)
Results were verified by a second approach (Figure 1) using a
recently developed technology combining chromatographic sepa-
ration by High Performance Thin Layer Chromatography (TLC)
and MALDI-TOF MS [21]. Organic extracts were spotted on
Silica Gel 60 HPTLC plates (Merck), pre-developed in chloro-
form-methanol (1:1, v/v) and separated sequentially by two mobile
phases: chloroform-ethanol-triethylamine-water (30:35:35:8, v/v/
v/v) and hexane-ether (100:4.5, v/v). DHB matrix (100 mg/ml) in
50% acetonitrile was spotted using an ImagePrep apparatus
(Bruker Daltonics) and a MALDI-TOF spectra scan in the positive
mode was obtained by the TLC-MALDI and FlexImaging
software packages (Bruker Daltonics). Ions of interest were
subjected to MALDI-TOF/TOF for structure determination
and eventual identification.
Results
After exclusion of matrix background and isotopic peaks, a total
of 100 relevant ions were detected in the neutral lipid fraction, 55
in the fatty acid fraction, and 58 in the phospholipid fraction, in
the positive mode analysis. In the negative mode, relevant ions (11
in total) were only detected in the free fatty acid fraction. Group
comparisons by ClinProTools
TM resulted in the detection of 18
ion peaks, all of them corresponding to the phospholipid fraction
analyzed in positive mode, differentially displayed with p-values
,0.05 (Table 2). Differences were established between CF (all
patients) vs non-CF children (14 peaks) and between patients
showing mild vs severe pulmonary disease (7 peaks). When mild
and severe patient groups were established according to Shwach-
man Score values (cutoff =65), analogous results were obtained
Figure 3. Box plots corresponding to four peaks differentially displayed. Two sphingomyelin (m/z 489.3 and 725.5, upper panels) and two
phosphatidylcholine (m/z 782.6 and 810.6, lower panels) species are represented. Relative intensity corresponds to the area of each peak of the
spectrum related to the total ion count. Box plots are constructed from log-transformed relative intensity data.
doi:10.1371/journal.pone.0007735.g003
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individuals were grouped according to pancreatic sufficiency,
gender or age.
Peaks of interest were subjected to LC-MS
n or MALDI-TOF/
TOF for structure determination and, eventually, for identifica-
tion. The identity of all the molecules was confirmed by MS/MS
fragmentation (this procedure is summarized in Figure 2). This led
to the unambiguous identification of 5 lysophosphatidylcholine
(LPC), 10 phosphatidylcholine (PC), and 2 sphingomyelin (SM)
species (Table 2) and one possible lysophosphatidylethanolamine
(LPE). LPE(18:0) and the sodium adduct of SM(d18:0) (sphinga-
nine-1-phosphocholine), were significantly increased in plasma
from all CF patients. PC included two alkyl-acyl and one alkenyl-
acyl (plasmalogen) form. In all cases the relative abundance of
LPC and PC was decreased in all CF patients vs non-CF
individuals. More interestingly, 7 of them, i.e. PC(36:3), PC(36:4),
PC(36:5), PC(O-38:0), PC(38:6) and PC(38:5), as well as the
sodium adduct of SM(16:0) were also significantly decreased in
severe as compared to mild CF patients.
Representative examples of differences between all patients,
healthy controls, mild and severe individuals are shown in Figure 3,
which depicts box plots for 4 molecules after log transformation of
raw data. The two lower panels correspond to PC forms (m/z
782.6 and 810.6) and the two upper to two SM (m/z 489.3 and
m/z 725.5). As a general observation, LPC moieties (see Table I)
were differentially displayed between all CF patients and healthy
children, but not between the mild and severe forms of disease.
Conversely, the differential presence of PC and SM species was
significant between both mild and severe patients and between
healthy and all sick individuals. The SM containing sphinganine as
the sphingoid base (m/z 489.3) is exceptionally increased in all CF
patients as compared to healthy controls.
The ability of differentially displayed peaks to segregate the
populations of individuals considered is represented by 2D peak
distribution diagrams (Figure 4). As shown in the plot, several
combinations of peaks can separate healthy from severe
individuals with a 95% confidence interval (i.e. 782.6/808.6 and
782.6/489.3, upper panels). Nevertheless, although there is a fairly
good separation of mild and severe individuals, some overlapping
occurs even if the best combination of peaks is chosen (806.6/
808.6 or 725.5/808.6, lower panels).
A parallel statistical analysis was performed by ANOVA after
log transformation of raw data corresponding to the phospholipids
fraction. The results are shown in Table 3. This study provided 26
peaks that changed significantly between healthy controls and all
CF patients, and 11 peaks that changed between mild and severe
patients. Concerning all CF vs nonCF evaluation, 11 peaks were
coincident with the results of the ClinProTools
TM analysis,
corresponding to SM(d18:0), LPC(18:0), LPC(18:2), LPC(20:3),
LPC(20:5), PC(36:5), PC(O-38:0), PC(38:4), PC(38:5), PC(38:6),
and PC(O-40:0). Concerning mild vs severe comparison, 4 peaks
were coincident with those provided by ClinProTools
TM, namely
PC(36:3), PC(36:5), PC(38:5) and PC(38:6). A hierarchical
clustering analysis of these peaks is shown in two heat maps, after
filtering according to either healthy vs all CF (Figure 5) or mild vs
severe (Figure 6). In both figures, two major clusters of individuals
can be observed: one represented on the left side, in which most of
the peaks are downregulated (blue), constituted by most of the
Figure 4. ClinProTools
TM 2D Peak Distribution diagrams corresponding to four couples of ions. Ellipses correspond to 95% confidence
intervals. Blue, green and red spots denote healthy subjects, mild patients and severe patients respectively.
doi:10.1371/journal.pone.0007735.g004
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predominant upregulation (red) of peaks. The peak corresponding
to m/z 489.3 (sphinganine-1-phosphocholine) represents an
exception, as its trend is opposite to the rest of peaks in most of
the individuals (Figure 5).
In order to illustrate the potential of our findings in the
screening of individuals, and given that the results concerned
phospholipid signatures, we chose a new technique (TLC-MALDI)
especially adapted to phospholipid analysis [21]. We analyzed the
raw extracts from one healthy control and one patient (none of
them included in the original study) to TLC-MALDI. Figure 7
shows 1D and 2D TLC-MALDI plots corresponding to both
individuals. As it can be observed in Figure 7A, LPC, SM and PC
signatures present generally stronger intensity in the control. The
color identification of selected peaks on the TLC plate by the
FlexImaging software (Fig. 7B) reveals a stronger signal for
LPC(18:0), SM(16:0) and PC(38:4) in the control sample, and a
weaker signal for SM(d18:0), which is consistent with the results
obtained in the study. This can be visualized by the chromato-
graphic integration performed by the TLC-MALDI software
(Fig. 7C). This is particularly clear in chromatograms for SM(16:0)
and PC(38:4). However, it must be considered that these results
are not quantitative, though they suggest a similar trend as those
obtained by ClinProTools
TM. This analysis represents the first
application of TLC-MALDI to human plasma samples, as well as
a complement to other MS methods used for identification of lipid
structures.
Discussion
In this study, we found some significant changes in the plasma
content of several phospholipids species in healthy vs all CF
individuals, and in mild vs severe CF patients. This includes a
significant decrease in a number of LPC and PC species in all CF
patients. This finding, confirmed by two independent statistical
approaches, is consistent with the majority of reports on lipid
alterations associated with CF that have been published to date.
However, two major points make these results novel and unique:
one technical and one physiopathological.
From the technical point of view, in this study we have used a
novel approach that reveals promising for further studies aiming at
the search for phenotypical markers associated with disease
severity and prognosis. It can be argued that the results obtained
correspond to some of the most abundant lipid species in
biological samples. In fact, for this first study we have chosen a
standard matrix, like DHB. This favors the detection in the
positive mode, and in particular that of PC species as compared to
other phospholipids. Nevertheless, we have been able to find
signatures corresponding to neutral lipids and free fatty acids, and
they were found statistically unchanged. On the other hand, the
purification method employed did not allow the analysis of less
abundant acidic phospholipids.
The search for prognostic lipid biomarkers of disease severity
and exacerbations should allow a better understanding of the
regulation of inflammation, the link between genotype and lipid
imbalances and the therapeutic potential of certain lipids. In this
report, we propose to apply a technique initially developed for the
exploration of protein biomarkers in the quest for lipid biomarkers.
Since it is based on MALDI technology, it is a fast and user-
friendly methodology, and compatible with several previous
extraction and separation approaches (i.e., liquid and column
chromatography). Yet, even though the statistical analyses
provided by ClinProTools
TM are robust, our results also suggest
the convenience of performing powerful statistical analyses in
parallel in order to validate the results obtained.
We also present TLC-MALDI as a complementary method
especially suitable for sample screening and for comparison of lipid
signatures from human fluids. In fact, TLC-MALDI gathers a
number of advantages. Firstly, it comprises a separation method
different from liquid or column chromatography, and more
reproducible, as several samples can be run in parallel exactly in
the same conditions. Secondly, the procedure has the rapidness
and user-friendliness of MALDI.
This semiquantitative method allows an ‘‘at a glance’’ way to
visualize the plasma lipidome of an individual at a particular time
and condition. It could be considered as the lipidomic equivalent
to the western blot in proteomics. In this sense, it represents an
ideal approach to detect evolving changes as a function of severity,
exacerbations of disease, and therapeutical interventions. It can be
a method of choice when the number of samples is limited, or to
verify the results obtained after a statistical analysis on samples that
have not been included in the analysis (as in this case) or chosen
Table 3. Peaks differentially displayed in either healthy
healthy vs CF patients (a) or in CF mild vs CF severe patients
(b) with p,0.05 after log transformation and ANOVA analysis.
m/z D(m/z) Differential display Identity
449.33 0.03 a MGL(22:0)
#
489.27 0.07 a SM(d18:0)
#
498.32 0.04 a PS(16:0)
#
510.34 0.05 a LPC(O-18:0)
520.31 0.02 a LPC(18:2)
524.35 0.02 a LPC(18:0)
542.3 0.02 ab LPC(20:5)
546.33 0.02 ab LPC(20:3)
703.58 0.01 a SM(16:0)
756.54 0.01 a PC(34:3)
758.55 0.02 a PC(34:2)
760.57 0.02 a PC(34:1)
762.59 0.01 a PC(34:0)
768.62 0.03 a PE(38:4)
780.53 0.01 ab PC(36:5)
782.52 0.02 a PC(36:4)
784,54 0.02 b PC(36:3)
786,59 0.01 b PC(36:2)
788.6 0.02 ab PC(36:1)
796.57 0.05 b PC(O-38:4) or
PC(P-38:3)
#
798.57 0.07 a PC(P-38:2)
804.54 0.13 a PC(O-38:0)
806.56 0.00 ab PC(38:6)
808.58 0.00 ab PC(38:5)
810.6 0.01 ab PC(38:4)
812.64 0.02 ab PC(38:3)
828.56 0.11 a PC(P-40:1)
832.56 0.16 a PC(O-40:1)
834.64 0.04 a PC(40:6)
All [M+H]
+ except 449.33 and 489.27, which correspond to [M+K]
+ and [M+Na]+
respectively. #Theoretical identity (not confirmed by MS
n).
doi:10.1371/journal.pone.0007735.t003
Plasma Lipidomics in CF
PLoS ONE | www.plosone.org 7 November 2009 | Volume 4 | Issue 11 | e7735randomly from the analysis group. The present report is, to our
knowledge, the first application of TLC-MALDI to lipid screening
in human plasma.
The next step in the search for prognostic lipid signatures in
plasma is to follow up patients during the development of the
disease and to compare the signatures from those who remain with
a mild phenotype with those who evolved to a severe one. This
long term prospective study needs a strong participation of a
clinical team, and a precise and standardized definition of mild
and severe phenotypes, which should not change during the course
of the study. Unfortunately, this is not the case at present. For
example, the definition of exacerbation is still a matter of
discussion among CF clinicians. Of note, our definition of severity
vs. mild is clearly described in the Methods section, and represents
a consensus between physicians from Poland, Sweden, and
France, as reached during our FP6 CE project (NEUPROCF).
Physiopathologically, we have found a significant correlation
between some of the decreased molecules and the severity status of
patients concerning respiratory symptoms. This includes 5 PC
forms containing highly unsaturated chains. This is in agreement
with the lower polyunsaturated fatty acid levels found in blood and
tissues from patients and models. Linoleic acid (18:2n26) has been
consistently found decreased in phospholipids, triacylglycerides
and cholesteryl esters in plasma and serum from CF patients
[28,29]. Docosahexaenoic acid (22:6n23) has been found
decreased in tissue phospholipids from cftr
2/2 null mice [15],
while arachidonic acid (20:4n26) is decreased in plasma and tissue
phospholipids from the cftrtm1HGU/tm1HGU mouse [30].
Nevertheless, our results cannot be compared directly with those
of previous studies on fatty acid profiling of CF patients, as they
respond to totally different approaches: analysis of intact molecules
in the present study and of cleaved fatty acid moieties in the latter.
Our observations can be roughly summarized as a consistent
decrease in several PC and LPC species in CF plasma. Other
authors have found similar results [31]. This can be attributed to (i)
maldigestion-malabsorption, (ii) abnormal metabolism in liver, (iii)
alterations in plasma lipoproteins or apolipoproteins, (iv) increased
degradation or turnover, or a combination of them.
As recently reported, lysophospholipids and phospholipids are
excreted at a higher extent in CF patients [32]. This is attributed
by the authors to a defect in fat absorption and choline depletion.
However, they do not find any differences in total phospholipid,
PC or LPC content in blood, which could be due to a defect in bile
function and is found concomitant with an increase in phospha-
tidylethanolamine conversion to PC in the liver. To this regard, it
is worth noting that in our study no significant differences are
Figure 5. Hierarchical clustering heat map representing increases (red) and decreases (blue) in intensity of peaks significantly
different in healthy vs CF patients. Peak masses are represented in the vertical axis, and individuals in the horizontal axis. Data were log-
transformed, obtained after clustering of peaks (vertical axis) and individuals (horizontal axis), analyzed by the Ward Agglomeration Algorithm, and
filtered for healthy vs CF patients comparison. The green trace delimits the data corresponding to the cluster of individuals that show consistent
changes in lipid content.
doi:10.1371/journal.pone.0007735.g005
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patients, in agreement with other reports [14,33]. This challenges
the hypothesis of an exclusive maldigestion-malabsorption origin.
If phospholipid metabolism is concerned, an important pathway
to consider is the methionine-homocysteine cycle, in which choline
via betaine provides methyl groups to regenerate S-adenosylmethi-
onine, an important element in the generation of PC and amino
acid precursors for glutathione [34,35]. Liver triacylglycerol
accumulation and oxidative stress are common in CF and also
occur in choline deficiency [36]. Reduced ratios of S-adenosylme-
thionine to S-adenosylhomocysteine and of PC to phosphatidyleth-
anolamine in plasma, and phospholipid malabsorption have also
beenreportedinCFchildren[36].Thesealtered valuesarereversed
by PC treatment [36] and also by administration of 5-methylte-
trahydrofolate [37]. Another enzyme involved in PC synthesis is
CTP:phosphocholine cytidylyltransferase. A recent work reports its
decreased expression in P.aeruginosa-infected murine CF lung
epithelium [38].However, the fact that one potentialsphingomyelin
form, coincident in mass with the sodium adduct of SM(d18:0)
(sphinganine-1-phosphocholine or lysosphingomyelin), which also
contains the phosphocholine head group, is significantly increased
in CF patients, represents an exception to the hypothesis of an
alteration in choline metabolism and/or availability.
The finding of a sphingolipid species increased in the plasma of
all CF patients vs healthy individuals recalls the recently reported
accumulation of ceramides in Cftr-deficent cells and the therapeutic
potential of the acid sphingomyelinase inhibitor amitriptilin [39].
Whether there is a link between the membrane ceramide and the
presence of a sphinganine-containing lysosphingomyelin in plasma
may represent an interesting field for future research. Sphinganine
is the saturated form of sphingosine, both sphingoid base
components of sphingomyelins. Sphinganine-containing molecules
are elevated in malignant tumors as compared to normal tissues
[40], and a higher content can be attributed to a decrease in
dihydroceramide desaturase activity. However, no information is
available on plasma levels of these compounds. Likewise, nothing is
known about the ceramide content in plasma of CF patients.
Concerning the alterations observed in LPC, our findings could
be attributed to the presence of spontaneously degraded forms of
PC moieties. However, no differences were found between mild
and severe patients. If LPC and PC alterations have independent
origins, a potential hypothesis for increased LPC is a higher
activity of lecithin-cholesterol acyl transferase (LCAT), which has
been reported in CF patients [41]. It must be noted that decreased
levels of unsaturated forms of LPC (containing 18:2n26o r
18:1n29 chains) have been described as markers of colorectal
Figure 6. Hierarchical clustering heat map representing increases (red) and decreases (red) in intensity of peaks significantly
different in mild vs severe patients. Peak masses are represented in the vertical axis, and individuals in the horizontal axis. Data were log-
transformed, obtained after clustering of peaks (vertical axis) and individuals (horizontal axis), analyzed by the Ward Agglomeration Algorithm, and
filtered for mild vs severe patients comparison. The green trace delimits the data corresponding to the cluster of individuals that show consistent
changes in lipid content.
doi:10.1371/journal.pone.0007735.g006
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same origin, this could involve either malabsorption or a defective
transport by lipoproteins or both.
To this regard, the fatty acid pool is decreased in plasma
lipoproteins from CF patients [43]. LDL and HDL are decreased in
serum from CF patients, along with apoB, apoA1 and cholesterol,
while VLDL and triglycerides are augmented, according to a
pioneering study [44]. A decreased synthesis of apoB and apoA-I in
intestinal epithelium from CF patients has recently been confirmed
[45], suggesting a direct effect of CFTR dysfunction on malabsorp-
tion and/or abnormal formation of lipoproteins.
Finally, plasma depletion in PC species could be due to an
increased utilization by cells. In CF fibroblasts and platelets, an
increased incorporation of choline into membranes has been
observed, in parallel to an unchanged PC content, suggesting an
increased PC turnover in these cells [46].
As a consequence of the lower PC concentration in plasma, its
availability for other tissues can be compromised. PC alterations in
CF have also been reported in lung, where it constitutes the main
component of surfactant. In this context, PC, along with other
surface-active phospholipids, has been found decreased in
tracheobronchial secretions from CF patients [47,48].
PC depletion may also reflect or have profound consequences
on cell membrane composition and architecture including that
of membrane micordomains. It has been demonstrated that
CFTR recruitment in detergent resistant micordomains partic-
ipates in the regulation of the cell response to infection and
inflammation [49,50]. Assuming that the PC and SM content in
micordomains is changed, one can postulate that the micro-
domain-related recruitment of CFTR may be modified. In
addition, phospholipids bind to cytoskeletal proteins, and as
such they may influence the trafficking of membrane proteins. It
has been observed, for example, that the NBD1 domain of
CFTR binds selectively to phosphatidylserine, and that its
mutated form (F508del), loses this ability. This selective binding
may play a role in the delivery of this protein to the plasma
membrane [51]. In both cases, a treatment aimed to modify the
p h o s p h o l i p i dc o n t e n to fc e l l sm a yr e p r e s e n taw a yt oc o r r e c tt h e
cell function in CF.
In conclusion, in addition to a general decrease in LPC and
PC species, as well as an increase in SM(d18:0) in the plasma
from CF vs healthy individuals, we show decreased levels of
PC(36:3), PC(36:5), PC(38:6), and PC(38:5) in plasma as a
potential signature of respiratory disease severity in CF. This
constitutes the first application of MALDI-TOF-ClinPro-
Tools
TM and of TLC-MALDI to lipidomic analysis of human-
derived samples, and an alternative approach for blood
lipidomics in CF.
Figure 7. TLC-MALDI analysis of raw extracts from one CF patient and one healthy control. A: 2D diagram representing m/z (horizontal
axis) and chromatographic separation (vertical axis) from patient and control samples. In both cases extraction was performed from 200 ml of plasma,
and an equal volume of extract was spotted on the TLC plate. B: 1D diagram representing the chromatographic separation on the TLC plate. Colors
correspond to individually selected m/z values by the FlexImaging software. C: Semiquantitative chromatographic integration by the TLC-MALDI
software, corresponding to the peaks selected in B from healthy control and patient samples. Arrows indicate the peaks corresponding to m/z 489.3
according to the chromatographic migration.
doi:10.1371/journal.pone.0007735.g007
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